INDICATIONS AND CLINICAL OUTCOMES OFUSINGTRIPLE ANTITHROMBOTIC THERAPY IN PATIENTSWITH ACUTE CORONARY SYNDROME | ||
| ALEXMED ePosters | ||
| Article 1, Volume 7, Issue 1, January 2025, Pages 22-23 | ||
| Document Type: Preliminary preprint short reports of original research | ||
| DOI: 10.21608/alexpo.2025.326804.1967 | ||
| Authors | ||
| Ahmed Mahmoud El Amrawy1; Gehan Magdy2; Amr Zaky3; Mohamed Mostafa Mohamed Abdellatif Elsakhawy* 3 | ||
| 1Department of Cardiology and Angiology, Faculty of Medicine- Alexandria University | ||
| 2Department of Cardiology, Faculty of Medicine, Alexandria University | ||
| 3Department of Cardiology and Angiology, Faculty of Medicine, University of Alexandria. | ||
| Abstract | ||
| An acute coronary syndrome (ACS) is a potentially life-threatening condition that occurs most commonly when transient or permanent thrombotic occlusion of the coronary vasculature results in myocardial ischaemia and/or infarction. Approximately 6–8% of patients undergoing PCI have an indication for long-term oral anticoagulants (OACs) due to various conditions such as AF, mechanical heart valves, or venous thromboembolism. Compared with oral anticoagulation therapy alone, the addition of DAPT to OAC therapy results in at least a two- to threefold increase in bleeding complications. Therefore, these patients should be considered at high risk of bleeding, and the indication for OAC should be reassessed and treatment continued only if a compelling indication exists. AIM OF THE WORK: The aim of the study was to detect the main indications, protocols, combinationsand outcomes of patients taking triple antithrombotic therapy (dual antiplatelets and oral anticoagulants) presenting to Alexandria main university hospitals with acute coronary syndrome. SUBJECTS AND METHODS: This is an observational prospective cohort study of patients presenting with acute coronary syndrome and have indications to receive oral anticoagulant therapy (triple antithrombotic therapy) at Alexandria Main University Hospital for 1 year between March 2022 and February 2023. | ||
| Keywords | ||
| An acute coronary syndrome (ACS); triple antithrombotic therapy; major cardiovascular events | ||
|
Supplementary Files
|
||
|
Statistics Article View: 17 |
||
